USPTO Patent Applications - Organic Chemistry (C07D)

Novel Nootropic Prodrugs of Phenethylamine

The USPTO has published a patent application (US20260085036A1) for novel nootropic prodrugs of phenethylamine, assigned to MiHKAL GmbH. The application describes compounds designed to improve phenethylamine uptake and reduce side effects, potentially for treating conditions like depression and PTSD.

New Polymers and Methods Patent Application

The USPTO has published a new patent application, US20260085336A1, detailing processes for forming pyridinedicarboxylic acid derivatives and copolymers. The application, filed on September 25, 2025, outlines biocatalytic methods and potential uses for these new materials.

Patent Application for Novel Compound Treating Neurodegeneration and Cardiovascular Diseases

The USPTO has published a patent application (US20260085083A1) for a novel compound and pharmaceutical composition developed by SHANDONG RUZHI BIOMEDICINE TECHNOLOGY CO., LTD. The compound is intended for preventing or treating neurodegenerative diseases and cardiovascular/cerebrovascular diseases.

Protein Degraders Patent Application

The USPTO has published a new patent application, US20260085075A1, related to protein degraders and their uses. The application was filed on August 19, 2025, by inventors Nello Mainolfi, Nan Ji, Yi Zhang, and Matthew M. Weiss.

Patent Application for Novel Crystalline Form of Amine Compound

The USPTO has published a patent application (US20260085071A1) for novel crystalline forms of an amine compound, 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine. The application also discloses pharmaceutical compositions and the use of these forms for treating diseases such as atopic dermatitis and urticaria.

Patent Application for Cancer Treatment Compounds

The USPTO has published a new patent application (US20260085070A1) for heterocyclic CBL-B inhibitors intended for the treatment of cancer. The application was filed on April 7, 2025, by inventors Yingzhi BI, Kenneth G. CARSON, and Geraldine Cirillo HARRIMAN.

Organic Compound and Light-Emitting Device Patent Application

The USPTO has published a patent application (US20260090268A1) for an organic compound and a light-emitting device incorporating it. The application details specific chemical structures and their application in electronic apparatus. The filing date was September 8, 2025.

Organic electronic element and compound for improved hole transport

The USPTO has published a new patent application, US20260090270A1, filed by TOSOH CORPORATION. The application describes an organic electronic element and a compound designed to improve hole transport ability, potentially enhancing performance in electronic devices.

Mitsubishi Gas Chemical Organic Thin Film Patent Application

The USPTO has published a new patent application from Mitsubishi Gas Chemical Company, Inc. for a compound and organic thin film technology. The application, filed on December 14, 2023, details a specific molecular structure intended for use in photoelectric conversion elements and imaging devices.

Patent Application: Organic Light Emitting Device Compound

The USPTO has published a new patent application, US20260090199A1, detailing a novel organic compound for use in organic light-emitting devices. The application describes a compound that may offer improved driving voltage, efficiency, and service life compared to existing technologies.

Patent for Heterocyclic Compound Organic Light Emitting Device

The USPTO has published a patent application for a heterocyclic compound intended for use in organic light-emitting devices. The application, filed by Eui-Jeong Choi and others, describes a compound that may improve device efficiency and lifespan.

Patent Application for NLO Chromophores with New Acceptors

The USPTO has published a patent application (US20260085190A1) filed by Lightwave Logic, Inc. The application describes nonlinear optical (NLO) chromophores designed to increase refractive index, offering advantages in speed, photostability, and thermal stability for electro-optic devices.

Patent Application for Chromophores with New Ring-Locked Donors

The USPTO has published a new patent application (US20260085189A1) filed by Lightwave Logic, Inc. The application describes novel nonlinear optical (NLO) chromophores with ring-locked donors designed to increase r33 and stability. The filing date was September 23, 2025.

Patent Application for Psilocin Derivatives for Treating Disorders

The USPTO has published a patent application (US20260085040A1) for psilocin derivatives, including carbohydrate and amino acid conjugates. These compounds are intended for the treatment of various neuropsychiatric, neurodegenerative, neuroinflammatory, and pain disorders.

Patent Application for GYS1 Inhibitors

The USPTO has published a patent application (US20260085034A1) for N-(BENZHYDRYL)CYCLOALKYLCARBOXAMIDE derivatives as inhibitors of Glycogen Synthase 1 (GYS1). The application details compounds and methods for preparing them, as well as methods for inhibiting GYS1 and treating GYS1-mediated diseases.

Patent Application for Artemisinic Acid Derivative Preparation

The USPTO has published a patent application (US20260085030A1) for an artemisinic acid derivative and its preparation method. The application, filed by Yunnan Botanee Bio-Technology Group Co., Ltd., aims to improve the water solubility of artemisinic acid and dihydroartemisinic acid while retaining their whitening, anti-inflammatory, and anti-tumor properties.

Chromophores with New Bridges that Increase Refractive Index

The USPTO has published a patent application (US20260085236A1) for Lightwave Logic, Inc., detailing new nonlinear optical (NLO) chromophores designed to increase refractive index. These chromophores offer improved electro-optic effects, modulation speed, photostability, and thermal stability, making them suitable for low-power, small-footprint electro-optic devices.

KDM1A Inhibitors for Disease Treatment Patent Application

The USPTO has published a new patent application (US20260085082A1) from Imago Biosciences, Inc. The application discloses new compounds and compositions for pharmaceutical use, specifically for inhibiting KDM1A and increasing gamma globin gene expression to treat diseases like acute myelogenous leukemia.

Patent Application: Janus Kinase Inhibitors by Chiesi Farmaceutici

The USPTO has published a patent application (US20260085077A1) filed by Chiesi Farmaceutici S.P.A. The application describes compounds of general formula (I) that inhibit Janus Kinase (JAK) family kinases. These compounds are intended for therapeutic use in treating inflammatory diseases.

Patent Application for Crystal Form of Aromatic Heterocyclic Compound

The USPTO has published a patent application (US20260085076A1) detailing a new crystal form (I and III) of an aromatic heterocyclic compound. The application also describes a production method and its use in treating diseases related to abnormal JAK-STAT signaling pathways.

Patent Application: Cancer Treatment Compositions and Methods

The USPTO has published a patent application (US20260085074A1) detailing compositions and methods for treating cancer by modulating K-Ras, a frequently mutated oncogene. The application was filed on June 17, 2025, by inventors Jonathan Ostrem, Ulf Peters, and Kevan M. Shokat.

Patent Application for Pyrazolylcarboxamide Compounds for Therapy

The USPTO has published a patent application (US20260085073A1) for pyrazolylcarboxamide compounds and their use in therapy. The application details compounds that inhibit MALT1 and their potential treatment for proliferative, inflammatory, or autoimmune disorders.

Method for Preparing Intermediate of Adrenergic Receptor Agonist

The USPTO has published a patent application detailing a new method for preparing an intermediate of an adrenergic receptor agonist. The method claims to offer improved yield, reduced cost, and milder reaction conditions, making it more favorable for commercial production. The application was filed on December 4, 2025.

USPTO Patent Application for Cancer Prodrugs

The USPTO has published a patent application (US20260085069A1) for novel prodrug compounds designed to treat cancer and other diseases by inhibiting Casein Kinase 2 alpha (CK2α). The application details specific chemical structures and their potential pharmaceutical uses.

Pritelivir Crystalline Form Patent Application

The USPTO has published a patent application (US20260085068A1) filed by Assembly Biosciences, Inc. on August 28, 2023. The application describes a novel crystalline form of the antiviral drug pritelivir, intended for the treatment of herpes virus.

Cyclic Sulfonamide RNR Inhibitors for Cancer Treatment

The USPTO has published a new patent application, US20260085067A1, detailing cyclic sulfonamide RNR inhibitors for cancer treatment. The application was filed on September 12, 2023, by inventors Anthony B. Pinkerton, Jacques Mauger, and Yen Pham Hong Truong.

LRRK2 Degrading Compounds for Parkinson's Disease Treatment

The USPTO has published a new patent application (US20260085066A1) detailing bifunctional compounds designed to degrade LRRK2, a protein implicated in Parkinson's Disease. The application covers pharmaceutical compositions and methods for treating LRRK2-associated disorders.

Patent for SGLT Inhibitor Synthesis Intermediate

The USPTO has published a patent application for a crystalline form of an intermediate useful in the synthesis of SGLT inhibitors. The application details a method to improve purification efficiency and minimize related substances in the final product, potentially increasing yield.

Patent Application: Benzofuranyl/Benzoxazolyl Compounds for Cancer Treatment

The USPTO has published a patent application (US20260085064A1) for substituted benzofuranyl and benzoxazolyl compounds, including their synthesis and use in treating cancer. The application was filed on May 2, 2025, by inventors from institutions including the University of Texas MD Anderson Cancer Center.

Patent Application: Benzamide Compounds for SARS-CoV-2 PLpro Inhibition

The USPTO has published a new patent application (US20260085063A1) detailing benzamide compounds and methods for inhibiting SARS-CoV-2 PLpro. The application was filed on August 19, 2025, by inventors Jun Wang, Bin Tan, and Prakash Daulat Jadhav.

Novel compounds as CK2 inhibitors for disease treatment

The USPTO has published a patent application (US20260085062A1) for novel compounds identified as CK2 inhibitors. These compounds are intended for the treatment and prevention of various diseases, including cancer, viral infections, and neurodegenerative disorders. The application details specific chemical structures and their potential pharmaceutical uses.

Patent Application: Phthalazine Derivatives as Pyruvate Kinase Modulators

The USPTO has published a new patent application (US20260085061A1) for phthalazine derivatives as pyruvate kinase modulators, assigned to Sitryx Therapeutics Limited. The application was filed on September 25, 2025.

Patent Application: Therapeutic Compounds - Orexin-1 Receptor Antagonists

The USPTO has published a new patent application (US20260085060A1) for therapeutic compounds that act as orexin-1 receptor antagonists. The application, filed on September 25, 2025, details compounds with structural formula (I), their preparation, and pharmaceutical uses.

System for updating medical facility uses AI

The USPTO has published a patent application for a system that uses AI to determine whether to update a medical facility. The system retrieves information from the facility, applies an AI model, and initiates maintenance or upgrades based on the determination. The application was filed on September 4, 2023.

Patent Application US20260085058A1 for SOS1 Degraders Treating Cancers

The USPTO has published patent application US20260085058A1, which relates to compounds that degrade son of sevenless homolog 1 (SOS1) and their use in treating cancers, particularly KRAS-mutant cancers. The application was filed on August 11, 2023.

OX1 Receptor Antagonists Patent Application

The USPTO has published a new patent application (US20260085056A1) filed on May 9, 2025, by NXERA PHARMA UK LIMITED. The application relates to novel compounds for treating neurological or psychiatric disorders associated with orexin receptors.

Patent Application for Recyclable Polymer Material and Monomer

The USPTO has published a patent application (US20260085055A1) for a novel monomer and a chemically recyclable polymer material comprising the same. The application, filed by the Korea Institute of Science and Technology, describes a monomer formed by bonding a pentagonal cyclic olefin molecule with a photosensitive molecule to enable chemical recycling.

Hispidin Derivative Synthesis Method and Use

The USPTO has published a patent application (US20260085054A1) detailing a new method for synthesizing Hispidin derivatives and their use in preparing lipid-lowering drugs. The application describes a process using readily available starting materials with potential for large-scale industrial application.

Patent Application for Benzofuran Derivatives as SIK Inhibitors

The USPTO has published a patent application (US20260085053A1) from BEONE MEDICINES I GMBH for benzofuran derivatives that act as SIK inhibitors. These compounds are intended for the treatment of various inflammatory diseases.

Patent Application for Furan Derivative Oxidation Process

The USPTO has published a patent application (US20260085052A1) detailing a new process for producing 2,5-furandicarboxylic acid. The application, filed by David Lee Sikkenga and Jan Hendrik Blank, describes a specific oxidation method involving furan derivatives, oxidants, solvents, and catalysts.

Patent Application for 2-Chloro-4-Fluoro-5-Nitrobenzoic Acid Preparation

The USPTO has published a patent application (US20260085051A1) detailing a novel nitration process for preparing 2-chloro-4-fluoro-5-nitrobenzoic acid. The assignee is ADAMA AGAN LTD. This compound is used in the synthesis of the herbicide saflufenacil.

Triple Kinase Inhibitors for Cancer Treatment

The USPTO has published a patent application (US20260085050A1) for triple kinase inhibitor compounds designed for cancer treatment. The application details compounds that inhibit EGFR, ALK, and MET simultaneously, along with methods for treating cancer using these inhibitors.

Ergothioneine Crystal Form Patent Application

The USPTO has published a patent application (US20260085049A1) for a novel crystal form of ergothioneine and its preparation method. The application details a method for producing high-purity ergothioneine with low moisture content, intended for use in dietary supplements, foods, and cosmetics.

ACSS2 Inhibitors for Cancer, Alcoholism, Viral Infections

The USPTO has published a patent application (US20260085048A1) detailing novel ACSS2 inhibitors and their potential uses in treating cancer, alcoholism, and viral infections. The application was filed on September 8, 2025.

Triphenylazole Compound Patent Application for Synucleinopathy Treatment

The USPTO has published a patent application (US20260085047A1) filed by Shiratori Pharmaceutical Co., Ltd. for a triphenylazole compound intended for the treatment or prevention of synucleinopathy. The application details the compound's structure and its potential use in pharmaceutical compositions.

Patent Application: Dual Function Compounds for Cancer Treatment

The USPTO has published patent application US20260085046A1, filed on August 7, 2025, for dual function compounds intended for cancer treatment. The application discloses compounds of Formula (I) and their use in treating cancer.

Patent Application for Nitrogen-Containing Heterocyclic Derivative Inhibitor

The USPTO has published a patent application (US20260085045A1) for a nitrogen-containing heterocyclic derivative inhibitor. The application details a compound, its preparation method, and its use in treating diseases such as cardiovascular and cerebrovascular conditions.

Salts and Solid Forms of 4-hydroxy-N,N-diisopropyltryptamine

The USPTO has published a patent application detailing new salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DIPT), including hemi-glutarate and hemi-succinate forms. These forms are disclosed for their potential use in treating neurological and psychiatric disorders.

Patent Application for 4-Amino-5-Methyl Pyridin-2-One Production Process

The USPTO has published a patent application (US20260085044A1) detailing an improved process for producing 4-amino-5-methyl-(1H)-pyridin-2-one and its derivatives. The application, filed by MinAscent Technologies GmbH, describes a method using ammonium salts under pressure without gaseous ammonia, aiming for high yield and purity while reducing container corrosion.

Patent Application: Initiator Mixture and Polymer Composition

The USPTO has published a new patent application (US20260085043A1) detailing an initiator mixture, a composition including it, and a polymer formed from the composition. The application was filed on September 18, 2025, by inventors from South Korea.